ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "12ec5031-4dea-4dbc-a436-ee21d9f77258"}, "_deposit": {"id": "2004669", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2004669"}, "status": "published"}, "_oai": {"id": "oai:u-ryukyu.repo.nii.ac.jp:02004669", "sets": ["1642838338003", "1642838407795"]}, "author_link": [], "item_1617186331708": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "Cell signaling modifiers for molecular targeted therapy in ATLL", "subitem_1551255648112": "en"}]}, "item_1617186419668": {"attribute_name": "Creator", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Mori, Naoki", "creatorNameLang": "en"}]}]}, "item_1617186476635": {"attribute_name": "Access Rights", "attribute_value_mlt": [{"subitem_1522299639480": "open access", "subitem_1600958577026": "http://purl.org/coar/access_right/c_abf2"}]}, "item_1617186609386": {"attribute_name": "Subject", "attribute_value_mlt": [{"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Adult T-cell leukemia/lymphoma"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Human T-cell leukemia virus type 1"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Signal transduction"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Apoptosis"}]}, "item_1617186626617": {"attribute_name": "Description", "attribute_value_mlt": [{"subitem_description": "Adult T-cell leukemia/lymphoma (ATTL) is a malignancy of peripheral T lymphocytes caused by human T-cell leukemia virus type 1 (HTLV-1) infection. Available therapies for ATLL have minimal efficacy, with few responders and poor survival. New therapies are clearly needed for ATTL patients. Three decades of research in this field has resulted in accumulation of a wealth of knowledge about the molecular pathways underlying the proliferation of HTLV-1-infected T cells. Inappropriate over- and under-activation of various signaling pathways can contribute to pathological processes such as neoplasia. Molecular and pharmacological interventions that target the aberrant state of activation are thus of potential therapeutic benefit. Here we review how signal transduction pathway components including nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), janus kinase-signal transducer and activator of transcription (JAK-STAT), and phosphatidylinositol 3-kinase (PI3K)-Akt contribute to the pathogenesis of ATLL. The targeted inhibition of such molecules to suppress the growth of HTLV-1-infected T cells both in vitro and in vivo is also discussed. The potential translation of such strategies into effective therapies for patients with ATLL may improve the poor outcome associated with this neoplasia.", "subitem_description_type": "Other"}, {"subitem_description": "\u8ad6\u6587", "subitem_description_type": "Other"}]}, "item_1617186643794": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_1522300295150": "en", "subitem_1522300316516": "Frontiers in Bioscience Publications"}]}, "item_1617186702042": {"attribute_name": "Language", "attribute_value_mlt": [{"subitem_1551255818386": "eng"}]}, "item_1617186783814": {"attribute_name": "Identifier", "attribute_value_mlt": [{"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/20.500.12000/10327"}]}, "item_1617186920753": {"attribute_name": "Source Identifier", "attribute_value_mlt": [{"subitem_1522646500366": "ISSN", "subitem_1522646572813": "1093-9946"}, {"subitem_1522646500366": "NCID", "subitem_1522646572813": "AA11735423"}]}, "item_1617186941041": {"attribute_name": "Source Title", "attribute_value_mlt": [{"subitem_1522650068558": "en", "subitem_1522650091861": "Frontiers in Bioscience"}]}, "item_1617187056579": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicPageEnd": "1489", "bibliographicPageStart": "1479", "bibliographicVolumeNumber": "14"}]}, "item_1617258105262": {"attribute_name": "Resource Type", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_1617265215918": {"attribute_name": "Version Type", "attribute_value_mlt": [{"subitem_1522305645492": "AM", "subitem_1600292170262": "http://purl.org/coar/version/c_ab4af688f83e57aa"}]}, "item_1617353299429": {"attribute_name": "Relation", "attribute_value_mlt": [{"subitem_1522306287251": {"subitem_1522306382014": "DOI", "subitem_1522306436033": "http://dx.doi.org/10.2741/3319"}}, {"subitem_1522306287251": {"subitem_1522306382014": "DOI", "subitem_1522306436033": "10.2741/3321"}}, {"subitem_1522306287251": {"subitem_1522306382014": "PMID", "subitem_1522306436033": "19273141"}}]}, "item_1617605131499": {"attribute_name": "File", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "download_preview_message": "", "file_order": 0, "filename": "Mori.Fig.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2004669/files/Mori.Fig.pdf"}, "version_id": "a8f1184a-1816-4fa5-8999-06096535d6db"}, {"accessrole": "open_access", "download_preview_message": "", "file_order": 1, "filename": "Mori.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2004669/files/Mori.pdf"}, "version_id": "3f8c93bf-333a-4306-8939-99bcd93a2059"}]}, "item_title": "Cell signaling modifiers for molecular targeted therapy in ATLL", "item_type_id": "15", "owner": "1", "path": ["1642838338003", "1642838407795"], "permalink_uri": "http://hdl.handle.net/20.500.12000/10327", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2009-05-29"}, "publish_date": "2009-05-29", "publish_status": "0", "recid": "2004669", "relation": {}, "relation_version_is_last": true, "title": ["Cell signaling modifiers for molecular targeted therapy in ATLL"], "weko_shared_id": -1}
  1. 学術雑誌論文
  2. その他
  1. 部局別インデックス
  2. 医学部

Cell signaling modifiers for molecular targeted therapy in ATLL

http://hdl.handle.net/20.500.12000/10327
http://hdl.handle.net/20.500.12000/10327
2323d0fe-b5e0-4e18-ae1d-a50e0d6febe0
名前 / ファイル ライセンス アクション
Mori.Fig.pdf Mori.Fig.pdf
Mori.pdf Mori.pdf
Item type デフォルトアイテムタイプ(フル)(1)
公開日 2009-05-29
タイトル
タイトル Cell signaling modifiers for molecular targeted therapy in ATLL
言語 en
作成者 Mori, Naoki

× Mori, Naoki

en Mori, Naoki

アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
主題
言語 en
主題Scheme Other
主題 Adult T-cell leukemia/lymphoma
言語 en
主題Scheme Other
主題 Human T-cell leukemia virus type 1
言語 en
主題Scheme Other
主題 Signal transduction
言語 en
主題Scheme Other
主題 Apoptosis
内容記述
内容記述タイプ Other
内容記述 Adult T-cell leukemia/lymphoma (ATTL) is a malignancy of peripheral T lymphocytes caused by human T-cell leukemia virus type 1 (HTLV-1) infection. Available therapies for ATLL have minimal efficacy, with few responders and poor survival. New therapies are clearly needed for ATTL patients. Three decades of research in this field has resulted in accumulation of a wealth of knowledge about the molecular pathways underlying the proliferation of HTLV-1-infected T cells. Inappropriate over- and under-activation of various signaling pathways can contribute to pathological processes such as neoplasia. Molecular and pharmacological interventions that target the aberrant state of activation are thus of potential therapeutic benefit. Here we review how signal transduction pathway components including nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), janus kinase-signal transducer and activator of transcription (JAK-STAT), and phosphatidylinositol 3-kinase (PI3K)-Akt contribute to the pathogenesis of ATLL. The targeted inhibition of such molecules to suppress the growth of HTLV-1-infected T cells both in vitro and in vivo is also discussed. The potential translation of such strategies into effective therapies for patients with ATLL may improve the poor outcome associated with this neoplasia.
内容記述タイプ Other
内容記述 論文
出版者
言語 en
出版者 Frontiers in Bioscience Publications
言語
言語 eng
資源タイプ
資源タイプ journal article
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
識別子
識別子 http://hdl.handle.net/20.500.12000/10327
識別子タイプ HDL
関連情報
関連識別子
識別子タイプ DOI
関連識別子 http://dx.doi.org/10.2741/3319
関連識別子
識別子タイプ DOI
関連識別子 10.2741/3321
関連識別子
識別子タイプ PMID
関連識別子 19273141
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1093-9946
収録物識別子タイプ NCID
収録物識別子 AA11735423
収録物名
言語 en
収録物名 Frontiers in Bioscience
書誌情報
巻 14, p. 1479-1489
戻る
0
views
See details
Views

Versions

Ver.1 2022-01-27 08:12:13.080276
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON

確認


Powered by WEKO3


Powered by WEKO3